Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00216424 · ClinicalTrials.gov registry record · Phase 4
Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma
A Phase 4 study, sponsored by James A. Haley Veterans Administration Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00216424: Clinical Trial Phase 4 study, sponsored by James A. Haley Veterans Administration Hospital.
NCT00216424 is a Phase 4 study that was terminated before completion, run by James A. Haley Veterans Administration Hospital. The registered enrollment target is 40 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00216424, a Phase 4 study, was terminated before completion, sponsored by James A. Haley Veterans Administration Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is designed primarily to establish efficacy and estimate resource utilization. The short-term hypothesis is that the dose of capecitabine (825 mg/m2 twice/day 5 days per week) during the course of radiation therapy is efficacious in locally advanced, non-metastatic rectosigmoid carcinoma and will improve resectability. The long-term working hypothesis is that if 3-D CRT is combined with the potentiating and additive effect of capecitabine one hopes to see improved and durable tumor response and survival with acceptable toxicity. In addition, it is expected that the simplicity of using an oral agent (capecitabine) will be associated with reduced cost and resource utilization.
Interventions
- DRUG Capecitabine (Xeloda)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-01 |
| Phase | Phase 4 |
Why NCT00216424 stopped before completion
NCT00216424 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Capecitabine (Xeloda) is the first listed.
NCT00216424 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00216424 about?
NCT00216424 is a clinical study titled "Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma". This study is designed primarily to establish efficacy and estimate resource utilization. The short-term hypothesis is that the dose of capecitabine (825 mg/m2 twice/day 5 days per week) during the course of radiation therapy is efficacious in locally advanced, non-metastatic rectosigmoid carcinoma ...
What is the current status of trial NCT00216424?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2005-02. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00216424?
The interventions under investigation include: Capecitabine (Xeloda) (DRUG).
Who is sponsoring clinical trial NCT00216424?
This trial is sponsored by James A. Haley Veterans Administration Hospital, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00216424's enrollment target sits among peer trials
40 1397th of 2000 higher than 533 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia